Your browser is no longer supported. Please, upgrade your browser.
Settings
XENE Xenon Pharmaceuticals Inc. daily Stock Chart
XENE [NASD]
Xenon Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.34 Insider Own0.20% Shs Outstand33.19M Perf Week-6.69%
Market Cap393.30M Forward P/E- EPS next Y-1.17 Insider Trans-10.76% Shs Float32.64M Perf Month-14.13%
Income-36.40M PEG- EPS next Q-0.31 Inst Own80.50% Short Float2.28% Perf Quarter-22.95%
Sales13.90M P/S28.30 EPS this Y5.20% Inst Trans45.78% Short Ratio3.04 Perf Half Y-12.74%
Book/sh5.43 P/B2.18 EPS next Y4.30% ROA-24.70% Target Price22.20 Perf Year10.23%
Cash/sh6.92 P/C1.71 EPS next 5Y- ROE-35.80% 52W Range7.00 - 18.45 Perf YTD-9.61%
Dividend- P/FCF- EPS past 5Y-29.80% ROI-42.80% 52W High-35.77% Beta1.33
Dividend %- Quick Ratio4.80 Sales past 5Y-24.80% Gross Margin- 52W Low69.29% ATR1.17
Employees100 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)40.96 Volatility7.75% 8.78%
OptionableYes Debt/Eq0.09 EPS Q/Q48.40% Profit Margin- Rel Volume3.99 Prev Close12.25
ShortableYes LT Debt/Eq0.00 EarningsMay 21 AMC Payout- Avg Volume244.92K Price11.85
Recom1.20 SMA20-11.19% SMA50-6.66% SMA200-1.29% Volume977,645 Change-3.27%
Jun-01-20Resumed Jefferies Buy $23
Mar-25-20Initiated Wedbush Outperform $23
Jan-08-20Initiated William Blair Outperform
Sep-20-19Initiated Guggenheim Buy $25
Aug-08-18Reiterated Stifel Buy $9 → $15
Mar-13-17Initiated Jefferies Buy $13
Oct-21-16Initiated Stifel Buy $18
Sep-26-16Initiated Guggenheim Buy $20
Apr-14-16Reiterated Jefferies Buy $10 → $13
Oct-30-15Resumed Jefferies Buy
Dec-02-14Initiated Canaccord Genuity Buy $15
Jun-01-20 04:20PM  
11:31AM  
May-25-20 08:28AM  
May-22-20 10:23AM  
04:30AM  
May-21-20 05:15PM  
04:01PM  
02:30PM  
May-14-20 04:01PM  
Mar-31-20 08:30AM  
Mar-28-20 12:12AM  
Mar-26-20 04:01PM  
Mar-23-20 09:06AM  
Mar-09-20 04:01PM  
02:30PM  
Mar-02-20 04:01PM  
Feb-14-20 11:11AM  
Feb-06-20 11:53AM  
Feb-04-20 11:44AM  
08:13AM  
Feb-03-20 11:11AM  
Jan-27-20 04:01PM  
Jan-24-20 10:26AM  
Jan-23-20 12:00PM  
07:24AM  
Jan-22-20 08:49PM  
04:01PM  
Jan-13-20 08:30AM  
Jan-10-20 08:08AM  
Dec-11-19 11:23AM  
Dec-07-19 08:45AM  
Dec-06-19 08:45AM  
Dec-03-19 05:23PM  
07:59AM  
Dec-02-19 07:45AM  
07:30AM  
Nov-21-19 09:44AM  
Nov-15-19 08:45AM  
Nov-11-19 09:45AM  
Nov-05-19 04:01PM  
Oct-29-19 04:30PM  
Oct-25-19 02:20PM  
Oct-16-19 08:30AM  
Oct-01-19 07:21AM  
Sep-25-19 04:05PM  
11:49AM  
Sep-24-19 09:36AM  
Sep-17-19 04:05PM  
Sep-09-19 04:01PM  
Sep-05-19 11:22AM  
Aug-14-19 12:51PM  
Aug-06-19 09:33PM  
Jul-31-19 04:01PM  
Jul-09-19 11:11AM  
Jun-14-19 06:55PM  
Jun-05-19 08:10AM  
Jun-03-19 05:58PM  
May-29-19 04:19PM  
May-21-19 03:18PM  
May-15-19 12:31PM  
May-07-19 05:19PM  
04:01PM  
Apr-30-19 04:01PM  
Apr-24-19 04:01PM  
Apr-04-19 09:00AM  
Mar-13-19 02:02AM  
Mar-06-19 04:01PM  
02:30PM  
07:39AM  
Feb-27-19 04:01PM  
Feb-26-19 07:30AM  
Jan-28-19 08:00AM  
Jan-18-19 12:24PM  
Jan-06-19 09:00PM  
Dec-26-18 02:14PM  
Dec-19-18 01:54AM  
Dec-03-18 07:30AM  
Nov-30-18 09:00AM  
Nov-19-18 01:51PM  
Nov-16-18 11:56AM  
Nov-15-18 09:41AM  
07:55AM  
Nov-07-18 04:02PM  
05:17AM  
Nov-06-18 04:01PM  
Oct-30-18 04:01PM  
Oct-12-18 08:27AM  
Oct-11-18 09:24AM  
Sep-17-18 04:15PM  
Sep-12-18 08:15PM  
04:01PM  
01:56PM  
Sep-11-18 08:25AM  
Sep-10-18 09:17PM  
Sep-06-18 06:30AM  
Aug-31-18 08:29AM  
Aug-29-18 06:05AM  
Aug-26-18 03:40PM  
Aug-21-18 01:39AM  
Aug-07-18 06:35PM  
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBIN SHERRINGTONEVP, Strategy & InnovationJun 01Option Exercise3.568,23029,29918,426Jun 02 05:40 PM
PIMSTONE SIMON N.CEOJun 01Sale14.433,00043,290255,186Jun 02 04:50 PM
HOLLER FRANK ADirectorMay 29Option Exercise3.563,08610,986122,041Jun 02 04:54 PM
PIMSTONE SIMON N.CEOMay 29Sale13.995,00069,950258,186Jun 02 04:50 PM
PIMSTONE SIMON N.CEOMay 26Option Exercise3.566,17221,972264,294May 28 05:02 PM
AZAB MOHAMMADDirectorDec 16Option Exercise3.563,08610,98660,647Dec 17 05:04 PM
PATOU GARYDirectorDec 04Option Exercise3.562,0577,32321,516Dec 06 05:12 PM
TARNOW MICHAEL MDirectorNov 21Option Exercise3.557,20125,53369,713Nov 22 01:30 PM
PIMSTONE SIMON N.CEOSep 20Sale9.5110,39598,856258,122Sep 24 06:14 PM
HOLLER FRANK ADirectorSep 20Sale9.395,20648,884118,955Sep 20 04:15 PM
HOLLER FRANK ADirectorSep 19Sale9.277,60070,452124,161Sep 20 04:15 PM
HOLLER FRANK ADirectorSep 18Sale9.284,36840,535131,761Sep 18 06:43 PM
PIMSTONE SIMON N.CEOSep 17Option Exercise3.5357,612203,381272,209Sep 18 07:06 PM
HOLLER FRANK ADirectorSep 17Sale9.325,06947,243136,129Sep 18 06:43 PM
AZAB MOHAMMADDirectorSep 13Sale9.312321457,561Sep 17 04:46 PM
HOLLER FRANK ADirectorSep 12Option Exercise3.0731,89298,052148,979Sep 13 08:13 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationSep 12Option Exercise3.076,17218,94812,064Sep 13 06:58 PM